Hedge Fund Database
The curated database of hedge funds that publish investor letters. Research by geography, strategy, and schools of thought.
| # | Fund | Strategy | Style | Geography | AUM | Latest Letter |
|---|---|---|---|---|---|---|
The curated database of hedge funds that publish investor letters. Research by geography, strategy, and schools of thought.
| # | Fund | Strategy | Style | Geography | AUM | Latest Letter |
|---|---|---|---|---|---|---|
As of Sep 30, 2026
Value Line Capital Appreciation Fund advanced 1.57% net of fees during the third quarter of 2026, outperforming both its blended 60% S&P 500 / 40% Bloomberg U.S. Aggregate Bond benchmark, which declined 0.05%, and the Morningstar Moderate Allocation Category average return of -0.80%. The fund maintained a steady balanced asset allocation, finishing the period with approximately 66% allocated to equities, 30% to fixed income, and 4% to cash reserves. Fixed income exposure remains entirely anchored in high-quality, investment-grade securities rated AAA through BBB. Macroeconomic conditions remained demanding across the quarter, shaped by persistent inflation, elevated energy prices, and rising interest rates. While interest-rate-sensitive sectors such as Utilities, Real Estate, and Industrials exhibited marked weakness, broader equity markets proved resilient on the back of stronger-than-expected corporate earnings. The portfolio team emphasized companies demonstrating durable balance sheets, sustained secular growth prospects, and superior fundamental expansion, evidenced by projected three-year forward sales growth of 29% and forward earnings growth of 37%. Equity alpha was primarily driven by selection and an overweight posture in Information Technology, which gained 9% against the sector benchmark return of 7%. Key technology rebound contributors included Strategy, Workday, Salesforce, CrowdStrike, and Microsoft. Conversely, Health Care allocations generated modest drag, hindered by quarterly underperformance in holdings such as Eli Lilly and Madrigal Pharmaceuticals.
Combining high-quality growth equities with superior projected revenue and earnings trajectories alongside an investment-grade fixed income allocation delivers strong risk-adjusted capital appreciation through changing economic regimes.
Portfolio holdings are projected to outpace broader market fundamentals, supported by estimated 3-year annual sales growth of approximately 29% and 3- to 5-year forward earnings growth of 37%.
Moderate Conviction Bullish
Market Conviction
Growth Outlook
Risk Appetite
Capital Deployment
Forward Guidance
Language Signal
Perceived Risk
Opportunity Density
Time Horizon
Top Conviction Themes
Key Catalysts
Every insight in this database connects to the original source. Read the actual thesis, see the actual concerns, and make your own call.
Buyside Digest has no business relationship, partnership, agency, sponsorship, endorsement, or affiliation with Value Line Capital Appreciation Fund or any other manager whose content appears on the Service, except where expressly stated. We do not receive Manager Content directly from managers in most cases; content is collected from publicly available sources. Managers have not necessarily reviewed, approved, authorized, or endorsed our display of their content, our editorial commentary, our metadata extraction, or our classifications. Use of a manager’s name is for accurate attribution and identification purposes only, under principles of nominative fair use.
Buyside Digest does not independently verify the regulatory status, registrations, licensing, qualifications, credentials, or professional standing of managers whose content appears on the Service. We do not represent that managers are properly registered with applicable regulatory bodies, that their content complies with applicable securities laws, or that their performance representations are accurate. Inclusion of a manager in our database is based on the publicly available nature of their content, not on our verification of their regulatory status or content compliance. Users are responsible for conducting their own due diligence on any manager.
Performance data, returns, assets under management (“AUM”), and similar figures displayed on this page are sourced from publicly available manager communications (including investor letters), public filings, or other third-party sources. Buyside Digest does not independently verify performance figures, calculate returns, or audit manager-reported data. Such figures: May be selectively reported by the manager; May use non-standard calculation methodologies; May not reflect fees, expenses, taxes, or other costs; May be inconsistent across reporting periods; May be outdated. Past performance is not indicative of future results. Performance figures should not be relied upon for investment decisions without independent verification. Users should request audited performance data directly from the manager and conduct their own due diligence.